These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35896278)

  • 1. Calamari, Hyperkalemia, and Renin-Angiotensin System Blockade.
    Janak E; Kramer H
    Clin J Am Soc Nephrol; 2022 Aug; 17(8):1116-1118. PubMed ID: 35896278
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
    Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
    Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA
    Cardiovasc Ther; 2012 Jun; 30(3):e156-66. PubMed ID: 21883995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperkalemia as a constraint to therapy with combination Renin-Angiotensin system blockade: the elephant in the room.
    Epstein M
    J Clin Hypertens (Greenwich); 2009 Feb; 11(2):55-60. PubMed ID: 19222668
    [No Abstract]   [Full Text] [Related]  

  • 6. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients.
    Lin HH; Yang YF; Chang JK; Ting IW; Kuo HL; Wang IK; Huang CC
    Ren Fail; 2009; 31(10):942-5. PubMed ID: 20030530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and management of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors.
    Weinstein J; Girard LP; Lepage S; McKelvie RS; Tennankore K
    CMAJ; 2021 Dec; 193(48):E1836-E1841. PubMed ID: 34872955
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperkalemia: a threat to RAAS inhibition?
    Schrier RW
    Nat Rev Nephrol; 2010 May; 6(5):245-6. PubMed ID: 20424624
    [No Abstract]   [Full Text] [Related]  

  • 12. Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease.
    Oktaviono YH; Kusumawardhani N
    Acta Med Indones; 2020 Jan; 52(1):74-79. PubMed ID: 32291375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting RAAS blockade in CKD with newer potassium-binding drugs.
    Georgianos PI; Agarwal R
    Kidney Int; 2018 Feb; 93(2):325-334. PubMed ID: 29276100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.
    Knoll GA; Sahgal A; Nair RC; Graham J; van Walraven C; Burns KD
    Am J Med; 2002 Feb; 112(2):110-4. PubMed ID: 11835948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized?
    Pappoe LS; Winkelmayer WC
    Drugs Aging; 2010 Feb; 27(2):87-94. PubMed ID: 20104936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New potassium binders reduce the risk of hyperkalaemia in patients treated with renin-angiotensin-aldosterone system inhibitors.
    Tamargo M; Tamargo J
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):193-194. PubMed ID: 29982385
    [No Abstract]   [Full Text] [Related]  

  • 18. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S; Khan A; Vincent A; Lau K
    Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperkalemia risk and treatment of heart failure.
    Segura J; Ruilope LM
    Heart Fail Clin; 2008 Oct; 4(4):455-64. PubMed ID: 18760757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.